West Coast Research, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$32,689	2
2024	Research	$217,769	16
2023	Research	$637,009	1,010
2022	Research	$634,647	1,076
2019	Research	$331,180	12

Breakdown

Who paid Research payments · program years 2019–2025

Moderna TX, Inc. $1,446,451 2,098 payments
AbbVie, Inc. $308,948 11 payments
Novartis Pharmaceuticals Corporation $68,567 5 payments
AstraZeneca Pharmaceuticals LP $29,328 2 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $634,647 1,076 payments
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $520,897 531 payments
M16-100 $308,948 11 payments
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age $276,408 488 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $66,467 4 payments
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $22,233 1 payment
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. $14,500 3 payments
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $7,095 1 payment
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $2,100 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.